National shortage vs local refill reality
FDA resolved the national tirzepatide shortage, but local pharmacy disruptions can still happen by dose, wholesaler, channel, and refill timing.
The FDA resolved the national tirzepatide shortage in October 2024, but patients can still run into localized supply disruptions as product moves through wholesalers, pharmacies, and dose-specific refill queues. Prior authorization timing, refill gaps, and whether the prescription is filled through a retail or direct channel can all change whether the medication is actually available when the patient needs it.
Lilly publishes different savings and self-pay paths depending on insurance status. Commercially insured patients and self-pay patients can see very different pricing rules, while government beneficiaries often follow a separate access path. Program terms can change, so the workflow matters more than any one static number copied off the internet.
Zepbound contains tirzepatide and is used with nutrition and activity changes for adult weight management. It is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity. It is not interchangeable with a promise of weight loss, insurance approval, or local stock.
Adults with obesity, or overweight and a weight-related condition, may qualify for weight treatment. OSA treatment requires the specified sleep-apnea diagnosis and obesity. Clinical review considers pregnancy, severe gastrointestinal problems, other medicines, and treatment continuity.
Confirm the indication and the exact pen or vial presentation. Start with the prescriber’s initiation schedule, learn device-specific administration, and plan nutrition, symptoms, monitoring, and refills. Review the visit, drug benefit, prior authorization, and any savings eligibility separately. Self-pay does not remove clinical monitoring needs.
Bring your weight and treatment history, medicines and supplements, relevant glucose, kidney, and lipid results, and the exact product you have used before. Mention previous side effects, eye disease, eating difficulties, and pregnancy plans. If insurance denied treatment, bring the denial and plan details.
Review a personal or family history of medullary thyroid cancer, MEN 2, severe stomach-emptying problems, pancreatitis, gallbladder disease, allergies, and pregnancy plans before treatment. Nausea, vomiting, constipation, or diarrhea can occur. Persistent severe abdominal pain or inability to keep fluids down needs emergency department assessment now. Call 911 for breathing difficulty, a severe allergic reaction, loss of consciousness or unsafe travel. Tell the anesthesia team about treatment before a procedure. Do not combine GLP-1 medicines or change the dose yourself. Use non-oral contraception or add a barrier method for four weeks after starting and each dose increase. Continue prescribed CPAP or other OSA treatment until the sleep clinician reviews whether it can change.
Review weight trend, appetite, food and fluid intake, bowel symptoms, and treatment tolerability. Check glucose and adjust other diabetes medicines with the prescriber when relevant. Agree on how to contact the team between visits and what to do if a refill is delayed. Continued treatment depends on benefit, safety, access, and your goals.
Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.
FDA determined the national tirzepatide injection shortage was resolved on December 19, 2024. That national decision does not guarantee that every pharmacy has every Zepbound strength or presentation. Check the current FDA shortage database and the dispensing pharmacy when arranging a refill; local distribution or inventory delays can still occur.
FDA explains that localized supply disruptions can occur as a medicine moves through manufacturers, distributors and local pharmacies, even after a national shortage is resolved. One pharmacy’s inability to fill your prescription does not by itself establish a national shortage. Ask about the exact strength and presentation, expected fill date and other dispensing options; tell the prescriber before a treatment interruption.
Contact the prescriber and dispensing pharmacy before the refill runs out. Ask whether another pharmacy can fill the same prescribed product and presentation. A treatment gap may affect the restart plan; follow the exact missed-dose instructions and do not double up, substitute an unapproved product or restart a high dose on your own.
No. LillyDirect provides access through licensed dispensing-pharmacy partners and requires a valid prescription. The pharmacy confirms details, payment and available delivery or retail-pickup options. That route does not establish that every presentation or refill can arrive by your preferred date. Confirm timing before running out and tell the prescriber about a delay; do not change the product or dose yourself.
FDA resolved the national tirzepatide shortage, but local pharmacy disruptions can still happen by dose, wholesaler, channel, and refill timing.
Starter doses, escalation doses, and maintenance doses can move differently in the supply chain, so patients should not assume every strength behaves the same way.
A prescription can still stall even when product exists if the authorization is not cleared, the channel is wrong, or the refill request is submitted too late.
Availability questions are really about continuity of care. The best plan is the one that can be started, escalated, and refilled without avoidable disruption.
Bronx
932 E 174th St, Bronx, NY 10460
A Bronx access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in West Farms, Crotona Park East, and nearby Bronx neighborhoods.
View weight-loss location Get directions
Queens
37-15 23rd Ave, Astoria, NY 11105
A Queens access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in Astoria, Ditmars, East Elmhurst, and nearby Queens neighborhoods.
View weight-loss location Get directions
Bronx
2063A Bartow Ave, Bronx, NY 10475
A Bronx access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in Co-op City, Pelham Bay, Baychester, and nearby Bronx neighborhoods.
View weight-loss location Get directions
Brooklyn
341 Eastern Pkwy, Brooklyn, NY 11216
A Brooklyn access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in Crown Heights, Prospect Heights, and nearby Brooklyn neighborhoods.
View weight-loss location Get directions
Long Island
232 W Old Country Rd, Hicksville, NY 11801
A Long Island access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in Hicksville, Plainview, Bethpage, and nearby Nassau County communities.
View weight-loss location Get directions
Queens
80-10 Northern Blvd, Jackson Heights, NY 11372
A Queens access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in Jackson Heights, Elmhurst, Corona, and nearby Queens neighborhoods.
View weight-loss location Get directions
Queens
90-18 Sutphin Blvd, Jamaica, NY 11435
A Queens access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in Jamaica, Briarwood, Richmond Hill, and nearby Queens neighborhoods.
View weight-loss location Get directions
Queens
30-07 36th Ave, Astoria, NY 11106
A Queens access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in Long Island City, Astoria, Sunnyside, and nearby Queens neighborhoods.
View weight-loss location Get directions
Long Island
135 Mineola Blvd, Mineola, NY 11501
A Long Island access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in Mineola, Garden City, Westbury, and nearby Nassau County communities.
View weight-loss location Get directions
Manhattan
259 1st Ave, New York, NY 10003
A Manhattan access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in StuyTown, East Village, Gramercy, and nearby Manhattan neighborhoods.
View weight-loss location Get directions
Brooklyn
308 Graham Ave, Brooklyn, NY 11211
A Brooklyn access point for provider-guided Zepbound visits, coverage planning, and follow-up support for patients in Williamsburg, Greenpoint, Bushwick, and nearby Brooklyn neighborhoods.
View weight-loss location Get directions
Discuss which tests are appropriate, how to prepare and how your results will be reviewed.
Open main Zepbound overview